SCHEMBL1360055

SCHEMBL1360055

COCCN(CCOC)C(=O)c1coc2c(C(C)(C)C)cc(-c3ccc[nH]c3=O)cc12

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.37
KDM4E B2RXH2 5/20 0.33
HSD17B10 Q99714 5/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 3/20 0.33
TSHR P16473 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
KMT2A Q03164 1/20 0.32
POLB P06746 1/20 0.32
THRB P10828 1/20 0.32
ABL1 P00519 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
CYP1A1 P04798 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1357867 0.96 CYP3A4 (0.36) CYP3A4KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL1359292 0.82 CYP3A4 (0.38) CYP3A4ABL1CYP1A1
SCHEMBL1360340 0.82 NAPRT (0.40) CYP3A4KDM4EGAAABL1CYP1A1
SCHEMBL1358064 0.81 CYP3A4 (0.38) CYP3A4KDM4EKMT2APOLBABL1
SCHEMBL1360734 0.81 MAOB (0.40) CYP3A4KDM4EALDH1A1HPGDTSHR
SCHEMBL1359870 0.81 CYP3A4 (0.34) CYP3A4HPGDTSHRGAA
SCHEMBL1358066 0.80 MAOB (0.42) CYP3A4KDM4EALDH1A1POLBTHRB
SCHEMBL1359874 0.79 POLB (0.38) CYP3A4KDM4EHSD17B10HPGDGAA
SCHEMBL1359878 0.79 ABL1 (0.41) CYP3A4KMT2AABL1RAB9A
SCHEMBL1358139 0.78 KMT2A (0.37) CYP3A4KDM4EHSD17B10ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US claimed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 EP claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS CYP3A4 713/4885KDM4E 2198/4885HSD17B10 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.